J. Arnaiz

Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH S

R. Kaiser, J. Gatell, K. Ruxrungtham, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Effects of Metformin Or Gemfibrozil on the Lipodystrophy of HIV-Infected Patients Receiving Protease Inhibitors

J. Gatell, E. Martinez, A. Milinkovic, 2002, Antiviral therapy.

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy

Andrew Phillips, Esteban Martínez, Xavier Carné, 2001, AIDS.

Chronic Pain Treatment With Cannabidiol in Kidney Transplant Patients in Uruguay.

J. Arnaiz, L. Curi, S. Orihuela, 2018, Transplantation proceedings.

Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients

D. Podzamczer, J. Gatell, E. Martinez, 2007, AIDS.

Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis

A. Cruceta, J. Miro, A. León, 2017, The Journal of antimicrobial chemotherapy.

Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.

D. Podzamczer, J. Gatell, E. Martinez, 2003, The New England journal of medicine.

Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load

D. Podzamczer, J. Gatell, P. Reiss, 2003, AIDS.

Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts *

J. Montaner, B. Clotet, E. Negredo, 2008, HIV medicine.